Hyperphosphorylated tau in young and middle-aged subjects.
about
Ushering in the study and treatment of preclinical Alzheimer diseaseImmunotherapeutic approaches for Alzheimer's diseaseThree dimensions of the amyloid hypothesis: time, space and 'wingmen'The preclinical phase of the pathological process underlying sporadic Alzheimer's diseaseOrigins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.Primary age-related tauopathy (PART): a common pathology associated with human agingNovel immunological approaches for the treatment of Alzheimer's disease.Early neurone loss in Alzheimer's disease: cortical or subcortical?Norepinephrine Protects against Amyloid-β Toxicity via TrkB.Genetic CJD with a novel E200G mutation in the prion protein gene and comparison with E200K mutation casesTherapeutic strategies for tau mediated neurodegeneration.Treatment of intermittent hypoxia increases phosphorylated tau in the hippocampus via biological processes common to agingEpigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer's disease: looking in the correct place at the right time?Interaction between pathogenic proteins in neurodegenerative disorders.The relationship between subcortical tau pathology and Alzheimer's disease.Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, β-amyloid toxicity, and astrocyte function.Developing therapeutic vaccines against Alzheimer's disease.Amyloid β-Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143-Further Implications for Alzheimer's TherapyQuantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease.Is sporadic Alzheimer's disease a developmental disorder?Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.Do astrocytes collaborate with neurons in spreading the "infectious" aβ and Tau drivers of Alzheimer's disease?Reply: the early pathological process in sporadic Alzheimer's disease.Amyloid or tau: the chicken or the egg?A sex difference in the onset of the latent learning impairment in rats.Amyloid imaging with [(18)F]florbetapir in geriatric depression: early-onset versus late-onset.Amyloid-β may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer's disease: a hypothesis.DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology.Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading.Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART.
P2860
Q27014791-538EDF79-7A98-4439-BF93-A08823E9F9F6Q28081278-FDD2A02D-3611-47FD-99A4-053900D2D60AQ28082768-798C1590-5E7D-4ABE-8CCA-1CDA3C77422AQ28083428-597160FD-8EA5-4A8C-B229-3D46410D6388Q30572288-ADD526F2-7051-4F89-BA9E-1B004E3BC5FFQ34445021-0656F35F-5D68-410C-8EA0-AD7CDF88E07DQ34562675-51274BB6-7BDB-4A8B-8C35-3730D2721D34Q35176873-AD599C95-3068-41EC-8317-48FAE180EEC6Q36467129-FC200F95-9FB7-42CF-A3F1-1204800C23B0Q37430566-558325DF-4E10-475A-95DC-78BFA12AA9F1Q37550818-907EE5B6-BA6E-4FDC-8532-73F1A9BC7967Q37565965-EA90CF6F-2D58-4D87-B64E-288482B975BBQ37590630-E2BEBF42-64BA-48CC-B0AA-6244AB5ADC91Q37969262-35995959-B698-41D2-8FFD-E0EAA10B40EDQ38027942-897F3119-834C-43E3-A883-8CCD4587CAC8Q38113683-4B4BB5C4-B0D4-48F7-AE3C-3C0DDA5F18F0Q38283992-6A5F0407-013E-4116-8B55-CE43129DAF92Q38400509-28BCE37B-E64F-496A-B1A9-53FB549804A1Q38636151-B39926B4-48EE-4837-8D91-9E592D806B23Q38803172-E331149E-5B0D-4436-AF32-9C1C78B636A1Q39002052-D5666B9D-7B6D-4AB7-83ED-F591705C4199Q39233501-F0D51415-9BC6-454F-85FC-32AF288890B6Q39466317-BAEAFB21-02B3-4BC7-8F22-64FB2F6D9A87Q42218999-D2AC7B3D-6AB6-414E-9D5E-4CEB03BCE4CCQ47685999-A9B14ACC-755D-472C-8692-4FDB146CE2EBQ47832745-5DC0A082-1EBB-4A0F-8C28-D75028A90E77Q47841011-4C325157-2486-49B4-99D9-9B11B7B49218Q48188000-D6E0EBFF-425C-4139-8782-79C7AF367587Q50860519-DC18D081-16D7-48CD-B5E0-5B0D4B8F0DF6Q53120805-96D02AE6-BABE-421B-81D2-30A837616037Q55251949-D686D8C9-2F3E-48F4-ABA4-5DBBD65487A3Q55405326-E667356C-E81C-4C57-BAD1-1AE336511CDC
P2860
Hyperphosphorylated tau in young and middle-aged subjects.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Hyperphosphorylated tau in young and middle-aged subjects.
@ast
Hyperphosphorylated tau in young and middle-aged subjects.
@en
type
label
Hyperphosphorylated tau in young and middle-aged subjects.
@ast
Hyperphosphorylated tau in young and middle-aged subjects.
@en
prefLabel
Hyperphosphorylated tau in young and middle-aged subjects.
@ast
Hyperphosphorylated tau in young and middle-aged subjects.
@en
P2860
P1476
Hyperphosphorylated tau in young and middle-aged subjects.
@en
P2093
Adila Elobeid
Irina Alafuzoff
P2860
P2888
P304
P356
10.1007/S00401-011-0906-Z
P577
2011-12-11T00:00:00Z